Independent PatientView Survey

Corporate Reputation of Pharma 2025/6; Survey now open

Questionnaires for the 2025/2026 corporate reputation survey (from a patient perspective) is now open:

Click here to access the survey in your own language

  • ■ Two decades of experience
    ■ An extensive evidence base of patient-group views
    ■ 47 companies involved
    ■ Now in its 15th year
    ■ Survey conducted in 23 languages
    ■ Analyses based on geographic regions and therapy area

47 pharmaceutical companies included in PatientView’s Corporate Reputation of Pharma 2025/2026:

New companies for 2025/2026 included in bold:

* AbbVie * Acadia Pharmaceuticals * Alnylam Pharmaceuticals * Amgen * Amicus Therapeutics * Angelini Pharma * Astellas Pharma * AstraZeneca (including Alexion) * Bayer * Biogen * BioMarin * Boehringer Ingelheim * Bristol Myers Squibb * Chiesi Farmaceutici * CSL Behring * Daiichi Sankyo * Eisai * Eli Lilly * Exelixis * Gilead Sciences * GSK * Incyte * Ipsen * Johnson & Johnson Innovative Medicine (J&JIM) * Jazz Pharmaceuticals * LEO Pharma * Lundbeck * Merck KGaA/EMD Serono * MSD/Merck & Co * Novartis * Novo Nordisk * Otsuka * Pfizer * PTC Therapeutics * Recordati * Regeneron Pharmaceuticals * Roche/Genentech/Chugai * Sanofi * Sarepta Therapeutics * Servier * Sobi * Takeda * UCB * Ultrageny * Vertex * Viatris* ViiV Healthcare

Click here for more on PatientView’s Corporate Reputation of Pharma report

For more information or to inquire about the Corporate Reputation of Pharma report, please contact PatientView using the form below.

    Up